Aerosol Delivery During Continuous High Frequency Oscillation for Simulated Adults During Quiet and Distressed Spontaneous Breathing

References

1. 1.↵
   1. Strickland SL,
   2. Rubin BK,
   3. Drescher GS,
   4. Haas CF,
   5. O'Malley CA,
   6. Volsko TA

   ; on behalf of American Association for Respiratory Care. AARC clinical practice guideline: effectiveness of nonpharmacologic airway clearance therapies in hospitalized patients. Respir Care 2013;58(12):2187–2193.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Ortiz-Pujols S,
   2. Boschini LA,
   3. Klatt-Cromwell C,
   4. Short KA,
   5. Hwang J,
   6. Cairns BA,
   7. et al

   . Chest high-frequency oscillatory treatment for severe atelectasis in a patient with toxic epidermal necrolysis. J Burn Care Res 2013;34(2):e112–e115.

   OpenUrl
3. 3.
   1. Morgan S,
   2. Hornik CP,
   3. Patel N,
   4. Williford WL,
   5. Turner DA,
   6. Cheifetz IM

   . Continuous high-frequency oscillation therapy in invasively ventilated pediatric subjects in the critical care setting. Respir Care 2016;61(11):1451–1455.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Ferguson A,
   2. Wright S

   . Innovative chest physiotherapy techniques (the MetaNeb system) in the intubated child with extensive burns. Respir Med Case Rep 2017;22:232–234.

   OpenUrl
5. 5.↵
   1. Smallwood CD,
   2. Bullock KJ,
   3. Gouldstone A

   . Pressure attenuation during high-frequency airway clearance therapy across different size endotracheal tubes: an in vitro study. J Crit Care 2016;34:142–145.

   OpenUrl
6. 6.↵
   1. Réminiac F,
   2. Vecellio L,
   3. Heuzé-Vourc'h N,
   4. Petitcollin A,
   5. Respaud R,
   6. Cabrera M,
   7. et al

   . Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv 2016;29(2):134–141.

   OpenUrl
7. 7.↵
   1. Dailey PA,
   2. Harwood R,
   3. Walsh K,
   4. Fink JB,
   5. Thayer T,
   6. Gagnon G,
   7. et al

   . Aerosol delivery through adult high flow nasal cannula with heliox and oxygen. Respir Care 2017;62(9):1186–1192.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   Food and Drug Administration (FDA), (2013). Metaneb 510(k) Summary (K124032). Silver Spring, MD: Food and Drug Administration (FDA). Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf12/K124032.pdf. Accessed May 23, 2019.
9. 9.↵
   1. Karashima T,
   2. Mimura-Kimura Y,
   3. Miyakawa K,
   4. Nakamura A,
   5. Shimahara F,
   6. Kamei H,
   7. et al

   . Variations in the efficiency of albuterol delivery and intrapulmonary effects with differential parameter settings on intrapulmonary percussive ventilation. Respir Care 2019;64(5):502–508.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Reychler G,
    2. Keyeux A,
    3. Cremers C,
    4. Veriter C,
    5. Rodenstein DO,
    6. Liistro G

    . Comparison of lung deposition in two types of nebulization: intrapulmonary percussive ventilation vs jet nebulization. Chest 2004;125(2):502–508.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Reychler G,
    2. Wallemacq P,
    3. Rodenstein DO,
    4. Cumps J,
    5. Leal T,
    6. Liistro G

    . Comparison of lung deposition of amikacin by intrapulmonary percussive ventilation and jet nebulization by urinary monitoring. J Aerosol Med 2006;19(2):199–207.

    OpenUrlPubMed
12. 12.↵
    1. Berlinski A,
    2. Willis JR

    . Albuterol delivery via intrapulmonary percussive ventilator and jet nebulizer in a pediatric ventilator model. Respir Care 2010;55(12):1699–1704.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Fang TP,
    2. Lin HL,
    3. Chiu SH,
    4. Wang SH,
    5. DiBlasi RM,
    6. Tsai YH,
    7. et al

    . Aerosol delivery using jet nebulizer and vibrating mesh nebulizer during high frequency oscillatory ventilation: an in vitro comparison. J Aerosol Med Pulm Drug Deliv 2016;29(5):447–453.

    OpenUrl
14. 14.↵
    1. Tarrant BJ,
    2. Le Maitre C,
    3. Romero L,
    4. Steward R,
    5. Button BM,
    6. Thompson BR,
    7. et al

    . Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology 2017;22(6):1084–1092.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Brzezinski LX,
    2. Riedi CA,
    3. Kussek P,
    4. Souza HH,
    5. Rosário N

    . Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients? J Bras Pneumol 2011;37(3):341–347.

    OpenUrlPubMed
16. 16.↵
    1. O'Malley CA

    . Device cleaning and infection control in aerosol therapy. Respir Care 2015;60(6):917–927.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Manor E,
    2. Gur M,
    3. Geffen Y,
    4. Bentur L

    . Cleaning and infection control of airway clearance devices used by CF patients. Chron Respir Dis 2017;14(4):370–376.

    OpenUrl